Clinical trials: Secondary Progressive Multiple Sclerosis (SPMS)
- Condition Secondary Progressive Multiple Sclerosis (SPMS)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals